Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
251
resultados
Última actualización
16/10/2026 [06:52:00]
Resultados 225 a 250 de 251
Resumen de: US20260294823A1
A pharmaceutical composition includes therapeutic nanoparticles including a core including insulin, a shell comprising chitosan, the shell disposed on the core, and a coating containing pectin and dextrin on the shell, and a pharmaceutically acceptable carrier and/or excipient. A method of forming the pharmaceutical composition includes adding a sodium tri-polyphosphate solution to a chitosan solution including the chitosan and acetic acid while stirring to form a shell solution, mixing a dextrin solution with an insulin solution to form a core solution, forming a pectin solution, mixing the shell solution, the core solution, and the pectin solution using a homogenizer to form a precursor mixture, aging the precursor mixture to form the nanoparticles, and mixing the nanoparticles with the pharmaceutically acceptable carrier and/or excipient.
Resumen de: US20260294831A1
0000 Compositions include a biological component and polysorbate, where the polysorbate is free of monoesters. The invention also provides pharmaceutically acceptable carriers and buffers comprising monoester-free polysorbate, detergent-core nanoparticles comprising monoester-free polysorbate, methods for producing the monoester-free polysorbate, and methods of manufacturing the pharmaceutical compositions using a monoester-free polysorbate.
Resumen de: US20260294824A1
The present invention provides a gluconic acid-coated selenium nanoparticle (GA-SeNP), which comprises a selenium nanoparticle and gluconic acid, wherein the gluconic acid is coated on the selenium nanoparticle to form a core-shell structure. GA-SeNPs can repolarize M2 macrophages into M1 macrophages and induce apoptosis of cancer cells through the generation of reactive oxygen species, thereby serving as the medicine for cancer treatment. A manufacturing method thereof is also provided.
Resumen de: US20260294841A1
0000 A method of reducing cell viability of colon cancer cells includes contacting an encapsulated gingerol composition with the colon cancer cells at a concentration of 15 to 100 μg/mL, wherein the encapsulated gingerol composition comprises gingerol nanoparticles extracted from Zingiber officinale, an ionic cross-linker, a polysorbate, and chitosan nanoparticles, wherein the ionic cross-linker is bonded to the chitosan. The encapsulated gingerol composition is a powder comprising nanoparticles having an average particle size of less than 100 nm, and contacting the encapsulated gingerol composition with the colon cancer cells reduces the cell viability of the colon cancer cells to 40% or less. A method of treating a bacterial infection with the encapsulated gingerol composition.
Resumen de: US20260295029A1
0000 The present invention relates to influenza immunogens and a vaccine platform for influenza viruses. In particular, the invention relates to a non-naturally occurring polypeptides comprising an engineered hemagglutinin lateral patch sequence and a secretion signal sequence, nucleic acids encoding the same, vectors containing the nucleic acids, nanoparticles containing the polypeptides, nucleic acids or vectors, cells containing the nanoparticles, polypeptides, nucleic acids or vectors, pharmaceutical compositions comprising the cells, nanoparticles, polypeptides, nucleic acids or vectors, vaccines comprising the pharmaceutical compositions and methods for immunization with the vaccines.
Resumen de: US20260295034A1
0000 The present invention relates to coronavirus immunogens and a vaccine platform for coronaviruses. In particular, the invention relates to a non-naturally occurring polypeptides comprising an engineered pathogen S2 subunit and a secretion signal sequence, nucleic acids encoding the same, vectors containing the nucleic acids, nanoparticles containing the polypeptides, nucleic acids or vectors, cells containing the nanoparticles, polypeptides, nucleic acids or vectors, pharmaceutical compositions comprising the cells, nanoparticles, polypeptides, nucleic acids or vectors, vaccines comprising the pharmaceutical compositions and methods for immunization with the vaccines.
Resumen de: US20260294808A1
Disclosed herein is a biomimetic proteolipid nanovesicle, comprising: an ionizable or cationic lipid; a phosphocholine-based phospholipid; a cholesterol; a leukocyte membrane protein; and an siRNA encapsulated by the biomimetic proteolipid nanovesicle; wherein the biomimetic proteolipid nanovesicle has a lipid-to-protein ratio of from about 1:65 to about 1:85 by weight. Further disclosed herein is a biomimetic proteolipid nanovesicle, comprising: an ionizable or cationic lipid; a phosphocholine-based phospholipid; a cholesterol; a leukocyte membrane protein; and an mRNA encapsulated by the biomimetic proteolipid nanovesicle; wherein the biomimetic proteolipid nanovesicle has a lipid-to-protein ratio of from about 1:80 to about 1:100 by weight.
Resumen de: US20260294821A1
0000 A magnetically drivenable antigen delivery unit is disclosed as including a magnetic nanoparticle to which an antigen is loaded, and a biodegradable material encapsulating the magnetic nanoparticle. A method of forming a magnetically drivenable antigen delivery unit using microfluidic droplet generation technique is disclosed as including forming a solution of a magnetic nanoparticle to which an antigen is loaded, gelatin methacryloyl (GelMA), and lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP). The invention also discloses a method for realizing lymph node targeted delivery by magnetically driving subunit antigens.
Resumen de: US20260294978A1
Allele-specific (AS) CRISPR-Cas9-mediated cleavage to induce selective loss of the extra chromosome, particularly in a trisomic context where the dosage imbalance is inherently deleterious, can treat Down Syndrome, an untreatable disorder. While it is suitable for individualized therapy, the instant invention provides a generalized treatment module that can be used for any Down Syndrome patient.
Resumen de: US20260295070A1
0000 The present invention provides peptides that selectively target adipose tissue and adipose stromal stem cells (ASCs). Accordingly, in some embodiments, the invention provides compositions and methods for selective delivery of compounds to adipose tissue and ASCs and methods of treating diseases and disorders through targeted compound delivery.
Resumen de: WO2026202873A1
The present invention discloses a uric acid-lowering composite raw material comprising a tart cherry-celery seed combination and bromelain, relating to the field of functional foods. The composition comprises tart cherry extract, celery seed extract, bromelain, and a lyoprotectant. Through intermolecular non-covalent bonding, the active ingredients form an ordered core-shell structure, wherein plant- derived ingredients combine into a composite core, and bromelain is adsorbed onto the outer surface to form a protein coating layer. This delivery structure is constructed entirely from the active ingredients themselves without extra synthetic polymer carriers, avoiding metabolic burden and safety risks. The components achieve functional matching through molecular-level ordered binding; the core protects liposoluble ingredients, while the shell stabilizes the structure, fully exerting synergistic effects.
Resumen de: WO2026204820A1
This polyalkylene glycol lipid is represented by formula (1). (R1 and R2 are each independently a hydrogen atom, an aliphatic hydrocarbon group having 15-22 carbon atoms, or an acyl group having 15-22 carbon atoms; 6≥k≥0, 6≥l≥0, 6≥m≥0 and k+l+m≥2; A is an oxygen atom, an ester bond, a carbonate bond, or a carbamate bond; B is a divalent hydrocarbon group having 1-4 carbon atoms; n is a number from 21 to 226; C is a divalent hydrocarbon group having 1-4 carbon atoms; D is an oxygen atom, an ester bond, a carbonate bond, a carbamate bond, a urea bond, or an amide bond; E is a single bond or a divalent hydrocarbon group having 1-6 carbon atoms; and G is an atomic group represented by formula (2a), formula (2b), formula (2c), formula (2d), formula (2e), or formula (2f) described in the description.)
Resumen de: WO2026202000A1
The invention refers to a compound of Formula I, or pharmaceutically acceptable salts or solvates thereof and further to a lipid nanoparticle composition.
Resumen de: US20260294934A1
0000 Suspension formulations of nanoparticles of clobetasol propionate are described. The suspensions can be used therapeutically to treat skin and ocular burns; to enhance wound healing; to prevent or reduce hypertrophic scarring/keloids; to treat allergic rhinitis/sinusitis, asthma, inner ear disorders including hearing loss, tinnitus, or vertigo, tenosynovitis, tendinitis, enthesitis or arthritis.
Resumen de: US20260294834A1
0000 Disclosed herein include novel blood-brain barrier (BBB)-crossing receptors on the BBB interface, targeting peptides and derivatives thereof capable of binding to the novel receptors, and related methods of using the receptors to increase the permeability of the BBB and to deliver an agent to a nervous system (e g. CNS).
Resumen de: WO2026206072A1
The present invention relates to a Kindlin-2-expressing gene therapy composition for osteoarthritis, using a non-viral bioresorbable delivery vehicle. It was confirmed that CaP prepared in the present invention is a non-viral delivery vehicle that can be stably introduced into cells and can deliver an expression vector into cells. It was also confirmed that, when a Kindlin-2 vector was introduced onto the surface of CaP particles and administered to an osteoarthritis animal model, osteoarthritis-induced pain was reduced and cartilage was protected from damage. Furthermore, it was confirmed that, when the Kindlin-2 vector was introduced onto the surface of CaP particles, delivery ability was increased, thereby enhancing osteoarthritis amelioration effects, compared to administration of Kindlin-2 alone.
Resumen de: WO2026207520A1
Provided herein are non-enzymatic systems comprising peptides having a DNA binding domain (DBD) fused to a p300 recruiter domain of DUX4 (p300R domain) and associated methods for modifying gene and protein levels in a cell. The p300R-DBD peptides selectively bind to a locus that are altered by methylation or acetylation of one or more histones and/or DNA methylation of one or more CpG islands. The systems may further comprise one or more guide RNA and may be formulated in lipid nanoparticles.
Resumen de: WO2026206775A1
Disclosed herein are particles, pharmaceutical compositions, and methods for the prevention and/or treatment of joint diseases in a subject, and methods of making same.
Resumen de: WO2026206986A1
Compositions, kits, methods of making and methods of use comprising a particle comprising at least three agonists that respectively bind to Cluster of Differentiation 3 (CD3), 4-1BB (aka CD137), and Interleukin 2 Receptor (IL-2R).
Resumen de: US20260295032A1
0000 The present disclosure relates to a method of delivering a molecule of interest to the spleen. The present disclosure also relates to a method of delivering lipid nanoparticles to the spleen. The present disclosure further relates to a method of inducing antigen-specific immunity in a subject. The present disclosure comprises using a cationic polymer simultaneously with or before the administration of a lipid nanovesicle encapsulating the molecule of interest.
Resumen de: US20260295082A1
0000 The present invention relates to a modified delivery carrier and use thereof. The modified delivery carrier comprises a delivery carrier and a targeting domain coupled to the delivery carrier, wherein the delivery carrier is used for loading an agent, and the targeting domain is capable of specifically targeting a surface antigen of an immune cell.
Resumen de: US20260294828A1
The current invention relates to a delivery system to deliver one or more cargo to one or more cells, wherein the cargo delivery system comprises at least a calixarene, a phospholipid, an additional lipid such as sterol. The invention further relates to a method of delivering cargo to a subject using the delivery system and a pharmaceutical composition comprising the delivery system. The invention also relates to the use of a calixarene in an immunogenic composition, wherein said composition comprises an immunogenic component encapsulated in a lipid nanoparticle (LNP) comprising said calixarene and wherein said LNP has an adjuvant effect in said immunogenic composition. The invention also relates to a vaccine, wherein said vaccine comprises an immunogenic component encapsulated in a lipid nanoparticle, wherein said lipid nanoparticle comprises at least one calixarene molecule and said lipid nanoparticle acts as an adjuvant in said vaccine. The invention also relates to a method of preparing an immunogenic composition and a composition comprising a lipid nanoparticle (LNP) adjuvant comprising calixarene.
Resumen de: US20260294827A1
The present disclosure in some aspects relates generally to nanoparticle compositions for oxygen delivery, method of use thereof, and method of preparation thereof. The present disclosure in some aspects relates generally to topical formulations capable of delivering oxygen to a tissue and methods of their use for treating diseases, such as hypoxemia.
Resumen de: US20260297618A1
0000 This disclosure relates to nucleic acid constructs for expression of GM2 activator (GM2A) protein, and viral vectors comprising said constructs useful for the treatment of AB-variant GM2 Gangliosidosis (ABGM2). Also provided are methods and uses of the vectors disclosed herein for the treatment of ABGM2.
Nº publicación: WO2026202366A1 01/10/2026
Solicitante:
UNIV BERLIN FREIE [DE]
BAYER AG [DE]
FREIE UNIVERSIT\u00C4T BERLIN
BAYER AKTIENGESELLSCHAFT
Resumen de: WO2026202366A1
The present invention relates to a compound according to general formula (L1)(L2)(L3)m(L4)n-X- PG, wherein L1, L2, L3, L4 denote independently from each other a lipid moiety; n is 0 or 1; m is 0 or 1; X is a linker moiety; and PG is a polyglycerol moiety.
BOPI
Sede Electrónica
